Price Alert

Tourmaline Bio Inc. (TRML)

NASDAQ: TRML · Real-Time Price · USD

22.29

-0.10 (-0.45%)

At close: Aug 15, 2025, 12:51 PM

-0.45% (1D)

Bid	22.22
Market Cap	572.6M
Revenue (ttm)	40K
Net Income (ttm)	-82.87M
EPS (ttm)	-3.44
PE Ratio (ttm)	-6.48
Forward PE	-4.99
Analyst	Buy

Ask	22.33
Volume	44,842
Avg. Volume (20D)	253,524
Open	22.56
Previous Close	22.39
Day's Range	21.91 - 22.72
52-Week Range	11.56 - 29.79
Beta	2.06

About TRML

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TRML

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TRML stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-2.59%

TRML stock has given up its prior loss. Tourmaline... Unlock content with Pro Subscription

2 months ago

-2.59%

Tourmaline Bio shares are trading lower. The company announced topline results from its ongoing Phase 2 TRANQUILITY trial.

News

Just now · zacks.com

Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know

The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

2 months ago · seekingalpha.com

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing paci...